Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...
Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...
Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...
Lumicera Health Services announced today it has secured a purchase agreement with Anda, Inc., an independent wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., for a lower-priced ...